130 related articles for article (PubMed ID: 37706268)
1. PET/CT in treatment response assessment in lung cancer. When should it be recommended?
Bin Essa N; Kaplar Z; Balaji N; Alduraibi A; Bomanji J; Groves AM; Lilburn DML; Navani N; Fraioli F
Nucl Med Commun; 2023 Dec; 44(12):1059-1066. PubMed ID: 37706268
[TBL] [Abstract][Full Text] [Related]
2. The lung cancers: staging and response, CT,
Owens C; Hindocha S; Lee R; Millard T; Sharma B
Br J Radiol; 2023 Aug; 96(1148):20220339. PubMed ID: 37097296
[TBL] [Abstract][Full Text] [Related]
3. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
5. PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort.
Brose A; Michalski K; Ruf J; Tosch M; Eschmann SM; Schreckenberger M; König J; Nestle U; Miederer M
Cancer Imaging; 2023 May; 23(1):45. PubMed ID: 37198668
[TBL] [Abstract][Full Text] [Related]
6. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
7. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
[TBL] [Abstract][Full Text] [Related]
8. Thoracic staging with
Schaarschmidt BM; Grueneisen J; Metzenmacher M; Gomez B; Gauler T; Roesel C; Heusch P; Ruhlmann V; Umutlu L; Antoch G; Buchbender C
Eur Radiol; 2017 Feb; 27(2):681-688. PubMed ID: 27180186
[TBL] [Abstract][Full Text] [Related]
9. PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment.
Iravani A; Turgeon GA; Akhurst T; Callahan JW; Bressel M; Everitt SJ; Siva S; Hofman MS; Hicks RJ; Ball DL; Mac Manus MP
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1869-1877. PubMed ID: 31190177
[TBL] [Abstract][Full Text] [Related]
10. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
[TBL] [Abstract][Full Text] [Related]
11. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the Art.
Castello A; Rossi S; Lopci E
Curr Radiopharm; 2020; 13(3):228-237. PubMed ID: 31886757
[TBL] [Abstract][Full Text] [Related]
13. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of dual-energy CT used as an add-on to 18F FDG PET/CT in the preoperative staging of resectable NSCLC with suspected single osteolytic metastases.
Wu H; Dong S; Li X; Shi L; Shao D; Zhang Q; Chen M; Cao Y; Thant M; Huang X
Lung Cancer; 2020 Feb; 140():80-86. PubMed ID: 31901595
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of recurrence and follow-up using FDG-PET/CT for postoperative non-small-cell lung cancer patients.
Toba H; Kawakita N; Takashima M; Matsumoto D; Takizawa H; Otsuka H; Tangoku A
Gen Thorac Cardiovasc Surg; 2021 Feb; 69(2):311-317. PubMed ID: 32909168
[TBL] [Abstract][Full Text] [Related]
16. Utility of fluorodeoxyglucose-positron emission tomography in the identification of new lesions in lung cancer patients for the assessment of therapy response.
Obrzut S; Bykowski J; Badran K; Hayeri MR; Hoh CK
Nucl Med Commun; 2010 Dec; 31(12):1008-15. PubMed ID: 20926977
[TBL] [Abstract][Full Text] [Related]
17. 18F-fluorodeoxyglucose positron emission tomography/computed tomography is useful in postoperative follow-up of asymptomatic non-small-cell lung cancer patients.
Toba H; Sakiyama S; Otsuka H; Kawakami Y; Takizawa H; Kenzaki K; Kondo K; Tangoku A
Interact Cardiovasc Thorac Surg; 2012 Nov; 15(5):859-64. PubMed ID: 22914804
[TBL] [Abstract][Full Text] [Related]
18. CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment.
Vahdat S; Oermann EK; Collins SP; Yu X; Abedalthagafi M; Debrito P; Suy S; Yousefi S; Gutierrez CJ; Chang T; Banovac F; Anderson ED; Esposito G; Collins BT
J Hematol Oncol; 2010 Feb; 3():6. PubMed ID: 20132557
[TBL] [Abstract][Full Text] [Related]
19.
Brodin NP; Tomé WA; Abraham T; Ohri N
PET Clin; 2020 Jan; 15(1):55-63. PubMed ID: 31735302
[TBL] [Abstract][Full Text] [Related]
20. Combination of Fluorine-18 Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography (¹⁸F-FDG PET/CT) and Tumor Markers to Diagnose Lymph Node Metastasis in Non-Small Cell Lung Cancer (NSCLC): A Retrospective and Prospective Study.
Zhai X; Guo Y; Qian X
Med Sci Monit; 2020 Jun; 26():e922675. PubMed ID: 32483109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
